Synthesis of Novel Acetyl‐11‐keto‐β‐boswellic Acid Derivatives as Potential Anti‐GBM Agents

Abstract

Acetyl‐11‐keto‐β‐boswellic acid (AKBA) is known to inhibit the growth of glioblastoma (GBM) cells and subcutaneous GBM. A series of acetyl‐11‐keto‐β‐boswellic acid (AKBA) derivatives containing the oxime‐ester functionality or amide side chains were synthesized, and their anti‐GBM activities were evaluated. Some of these compounds exhibited significant inhibitory activity against cell proliferation in U87 and U251 GBM cell lines, with IC50 values in the micromolar concentration range. Cellular thermal shift analysis showed that A‐01 and A‐10 improved the thermal stability of FOXM1, indicating that these highly active compounds may directly bind to FOXM1 in cells. Docking studies of the two most active compounds, A‐01 and A‐10, revealed key interactions between these compounds and the active site of FOXM1, in which the amide moiety at the C‐24 position was essential for improving the activity. These results suggested that A‐10 is a suitable lead molecule for the development of FOXM1 inhibitors. Thus, the rational design of AKBA derivatives with amide side chains holds significant potential for discovering of a new class of triterpenoids capable of inhibiting GBM cell proliferation.